Invention of Enmetazobactam: An Indian Triumph in Antimicrobial Drug Discovery
- 19 December 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (1) , 1-3
Abstract
The discovery of antimicrobials was an inflection point in human existence since it contributed enormously to the extension of the human lifespan. Among others, the invention of Enmetazobactam marks a significant milestone in the field of antimicrobial development, especially for India. It is a novel beta-lactamase inhibitor invented by scientists at Orchid Pharma in Chennai, India, and has garnered international attention for its potential to address antimicrobial resistance. It became the first new chemical entity invented in India, clinically developed by Allecra Therapeutics GmbH, to be approved by the U.S. Food & Drug Administration, with additional approvals from the European Medical Agency, the U.K.'s Medicine & Healthcare Products Regulatory Agency, and the Drug Controller General of India.Keywords
This publication has 5 references indexed in Scilit:
- Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative BacteriaAntibiotics, 2024
- Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute PyelonephritisJAMA, 2022
- Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016–2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactamJournal of Global Antimicrobial Resistance, 2021
- In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014–2015Antimicrobial Agents and Chemotherapy, 2019
- Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam−β-Lactamase Inhibitor CombinationAntimicrobial Agents and Chemotherapy, 2019